Drug evaluation: the C5a receptor antagonist PMX-53.
Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.
Köhl
Jörg
J
Cincinnati Children's Hospital Research Foundation, Division of Molecular Immunology, MLC 7021, Cincinnati, OH 45229, USA. Joerg.Koehl@chmcc.org
D000818:Animals; D000936:Antigen-Antibody Complex / Q000187:drug effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D051056:Complement Inactivating Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000276:immunology; D008268:Macular Degeneration / Q000188:drug therapy / Q000276:immunology; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D009410:Nerve Degeneration / Q000188:drug therapy / Q000276:immunology; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D044087:Receptor, Anaphylatoxin C5a / Q000037:antagonists & inhibitors; D011951:Receptors, Complement / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000936:Antigen-Antibody Complex; C488033:C5AR1 protein, human; D051056:Complement Inactivating Agents; D008565:Membrane Proteins; D010456:Peptides, Cyclic; D044087:Receptor, Anaphylatoxin C5a; D011951:Receptors, Complement